Entrada Therapeutics (NASDAQ:TRDA) Raised to Hold at Wall Street Zen

Entrada Therapeutics (NASDAQ:TRDA) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts also recently commented on TRDA. Guggenheim lowered their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Monday, June 8th. Roth Capital reiterated a “buy” rating and set a $11.00 target price on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. HC Wainwright lowered Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, August 31st. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Entrada Therapeutics Stock Performance

Shares of TRDA opened at $7.13 on Friday. Entrada Therapeutics has a 1 year low of $5.02 and a 1 year high of $16.45. The company’s 50 day simple moving average is $7.06 and its 200 day simple moving average is $9.18. The company has a market capitalization of $277.64 million, a price-to-earnings ratio of -1.80 and a beta of -0.25.

Entrada Therapeutics (NASDAQ:TRDA) last released its earnings results on Wednesday, August 5th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.32 million. Equities analysts expect that Entrada Therapeutics will post -4.03 EPS for the current fiscal year.

Insider Transactions at Entrada Therapeutics

In other Entrada Therapeutics news, Director Kush Parmar sold 114,756 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $6.93, for a total transaction of $795,259.08. Following the completion of the sale, the director directly owned 2,848,310 shares in the company, valued at $19,738,788.30. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the company’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total value of $199,975.88. Following the completion of the sale, the insider directly owned 4,332,917 shares of the company’s stock, valued at $32,670,194.18. The trade was a 0.61% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 687,124 shares of company stock valued at $4,819,524. 9.49% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Entrada Therapeutics

Several institutional investors have recently bought and sold shares of the stock. State of Wyoming acquired a new position in shares of Entrada Therapeutics in the 2nd quarter worth approximately $37,000. Russell Investments Group Ltd. lifted its stake in Entrada Therapeutics by 72.7% during the third quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock valued at $51,000 after purchasing an additional 3,707 shares during the last quarter. Occudo Quantitative Strategies LP acquired a new stake in Entrada Therapeutics during the second quarter valued at approximately $68,000. IHT Wealth Management LLC acquired a new stake in Entrada Therapeutics during the second quarter valued at approximately $72,000. Finally, Jain Global LLC bought a new stake in Entrada Therapeutics during the third quarter worth approximately $69,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.